BLAINJECTIONINJECTABLE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FULPHILA (pegfilgrastim-jmdb) by Viatris (2) is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2018.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FULPHILA (pegfilgrastim-jmdb) is a biosimilar granulocyte colony-stimulating factor (G-CSF) approved in 2018 as a Viatris product. It stimulates proliferation and differentiation of hematopoietic cells to reduce chemotherapy-induced neutropenia and related infections. The drug works by binding to cell surface receptors on leukocyte precursors, triggering immune cell production.
$0.624MPart D
PeakProduct is at peak commercial stage with modest Medicare Part D uptake; team size likely stable with focus on maintaining market position against biosimilar competition.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FULPHILA career opportunities center on defending market share in a crowded biosimilar G-CSF market, with emphasis on payer negotiations, health economics, and competitive intelligence. Roles prioritize managed markets expertise and field execution over clinical development, making this suitable for early-to-mid career professionals in commercial and market access functions.
Brand Manager
Worked on FULPHILA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.